. Author manuscript; available in PMC: 2011 Nov 15.

Published in final edited form as: Mov Disord. 2010 Nov 15;25(15):2536–2541. doi: 10.1002/mds.23314

Table 2. Cancer in LRRK2 mutation and Non-LRRK2 mutation PD Subjects.

	All PD (n=163)	LRRK2 mutation PD (n=31)	Non-LRRK2 Mutation PD (n=132)	LRRK2 mutations vs. Non-LRRK2
Non-skin cancer (%)	24 (14.7%)	9 (29.0%)	15 (11.4%)	^*HR: 2.9 (1.3-6.6)
Age onset first non- skin cancer, years ^**	60.5 (56, 67)	56.0 (54, 68)	62.0 (57, 66)	^***p=0.5
Cancer before PD (%)	14 (8.6%)	6 (66.7%)	8 (40.0%)	^****OR: 3.7 (1.2-11.7)

Cox proportional hazards model, Hazards Ratio, 95% CI; adjusting for smoking: HR 2.8 (1.2-6.5); adjusting for smoking and gender HR 2.8 (1.2-6.4)

^**

median (interquartile range)

^***

Mann-Whitney p-value

^****

Logistic regression model, Odds Ratio, 95% CI